Article in Journal of natural products, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jesus E Sotelo-MoralesDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080, United States.
Sahar Mofidi TabatabaeiDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, United States.
Christian K FofieDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080, United States.
Kelvin K FosuBiodesign Center for Personalized Diagnostics and School of Molecular Sciences, Arizona State University, Tempe, Arizona 85287, United States.ORCID 0000-0002-6299-2354
Joseph B Dodd-ODepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey 07102, United States.
Rebekah D SimcikDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080, United States.ORCID 0009-0007-6006-7273
See H TackDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080, United States.
Miguel J Soto-ReyesDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico 00936, United States.
Muhammad Saad YousufDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080, United States.ORCID 0000-0003-0829-8182
Eduardo J E Caro-DiazDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Puerto Rico - Medical Sciences Campus, San Juan, Puerto Rico 00936, United States.ORCID 0000-0002-2049-6248
Vivek A KumarDepartment of Biomedical Engineering, New Jersey Institute of Technology, Newark, New Jersey 07102, United States.ORCID 0000-0001-7536-9281
Wade D Van HornBiodesign Center for Personalized Diagnostics and School of Molecular Sciences, Arizona State University, Tempe, Arizona 85287, United States.ORCID 0000-0002-2493-5578
Benedict KolberDepartment of Biological Sciences, Department of Neuroscience, and Center for Advanced Pain Studies, University of Texas at Dallas, Richardson, Texas 75080, United States.ORCID 0000-0001-8665-1805
Kevin J TidgewellDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky 40536, United States.ORCID 0000-0002-0501-2604
Funding
Understanding the role of anti-apolipoprotein A-I antibodies in atherosclerotic cardiovascular diseaseP20GM130456 · NIGMS · UNIVERSITY OF KENTUCKY · PI Jon Scott Thorson · 2020 to 2026
$18.7M
Planning Study for the Development of Sigma 2 ligands as AnalgesicsR61NS127271 · NINDS · UNIVERSITY OF KENTUCKY · PI KOLBER, BENEDICT J, TIDGEWELL, KEVIN JOSEPH · 2023 to 2023
$1.5M
Cyanobacterial Natural Products to Treat Comorbid Pain and DepressionR15AT008060 · NCCIH · DUQUESNE UNIVERSITY · PI KOLBER, BENEDICT J, TIDGEWELL, KEVIN JOSEPH · 2014 to 2019
$905k
High content analgesic screening from human nociceptorsR33AT011938 · NCCIH · UNIVERSITY OF TEXAS DALLAS · PI DUSSOR, GREGORY O, KOLBER, BENEDICT J · 2024 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Veraguamide E, a Marine Cyanobacterial Depsipeptide Targeting σ · full record | OpenQuestion